Development of Personalised Cancer Vaccines
Next generation sequencing of tumour biopsies allows personalised identification of cancer-specific mutations. This information may reveal cancer-specific epitopes i.e. neo-epitopes that be developed into personalised cancer vaccines to boost a patient’s own immune response towards their specific cancer. Personalised cancer vaccines are seen as an important part of the next generation of rational cancer immunotherapy.
Immunitrack’s NeoScreen® platform technology supports early stage development of personalised cancer vaccines. NeoScreen® facilitates rapid high-throughput screening of major histocompatibility complex class I and II (MHC I & II) interactions with neo-epitopes to identify candidate epitopes for further development.